GSK plc (LON:GSK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

GSK plc (LON:GSK) has earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is GBX 1,805.83 ($22.73).

GSK has been the topic of a number of analyst reports. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank decreased their target price on GSK from GBX 1,820 ($22.91) to GBX 1,600 ($20.14) and set a “buy” rating on the stock in a report on Friday, November 29th.

Insider Transactions at GSK

In other news, insider Jonathan Symonds purchased 1,500 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were acquired at an average price of GBX 1,315 ($16.55) per share, with a total value of £19,725 ($24,826.94). Also, insider Emma Walmsley sold 120,653 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.29), for a total value of £1,753,088.09 ($2,206,530.01). Company insiders own 1.61% of the company’s stock.

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,435 ($18.06) on Friday. The business’s fifty day moving average price is GBX 1,367.43 and its two-hundred day moving average price is GBX 1,454.89. GSK has a fifty-two week low of GBX 1,282.50 ($16.14) and a fifty-two week high of GBX 1,823.50 ($22.95). The stock has a market capitalization of £58.23 billion, a price-to-earnings ratio of 23.18, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.